REFERENCES
1. Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 2019;156:254-272.e11.
2. Wiese ML, Urban S, von Rheinbaben S, et al. Identification of early predictors for infected necrosis in acute pancreatitis. BMC Gastroenterol 2022;22:405.
3. Weiss FU, Laemmerhirt F, Lerch MM. Acute pancreatitis: genetic risk and clinical implications. J Clin Med 2021;10:190.
4. Gorry MC, Gabbaizedeh D, Furey W, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology 1997;113:1063-8.
6. Girodon E, Rebours V, Chen JM, et al. Clinical interpretation of
7. Comfort MW, Steinberg AG. Pedigree of a family with hereditary chronic relapsing pancreatitis. Gastroenterology 1952;21:54-63.
8. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996;14:141-5.
9. Coté GA, Yadav D, Slivka A, et al. North American Pancreatitis Study Group. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2011;9:266-73; quiz e27.
10. Rebours V, Boutron-Ruault MC, Schnee M, et al. The natural history of hereditary pancreatitis: a national series. Gut 2009;58:97-103.
11. Howes N, Lerch MM, Greenhalf W, et al. European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC). Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004;2:252-61.
12. Sultan M, Werlin S, Venkatasubramani N. Genetic prevalence and characteristics in children with recurrent pancreatitis. J Pediatr Gastroenterol Nutr 2012;54:645-50.
13. Sahin-Tóth M. Human cationic trypsinogen. Role of Asn-21 in zymogen activation and implications in hereditary pancreatitis. J Biol Chem 2000;275:22750-5.
14. Teich N, Le Maréchal C, Kukor Z, et al. Interaction between trypsinogen isoforms in genetically determined pancreatitis: mutation E79K in cationic trypsin (PRSS1) causes increased transactivation of anionic trypsinogen (PRSS2). Hum Mutat 2004;23:22-31.
15. Kereszturi E, Szmola R, Kukor Z, et al. Hereditary pancreatitis caused by mutation-induced misfolding of human cationic trypsinogen: a novel disease mechanism. Hum Mutat 2009;30:575-82.
16. Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000;25:213-6.
17. Schneider A. Serine protease inhibitor kazal type 1 mutations and pancreatitis. Clin Lab Med 2005;25:61-78.
18. Király O, Boulling A, Witt H, et al. Signal peptide variants that impair secretion of pancreatic secretory trypsin inhibitor (SPINK1) cause autosomal dominant hereditary pancreatitis. Hum Mutat 2007;28:469-76.
19. Szmola R, Sahin-Tóth M. Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht’s enzyme Y. Proc Natl Acad Sci USA 2007;104:11227-32.
20. Rosendahl J, Witt H, Szmola R, et al. Chymotrypsin C (
21. Anderson MP, Rich DP, Gregory RJ, Smith AE, Welsh MJ. Generation of cAMP-activated chloride currents by expression of CFTR. Science 1991;251:679-82.
23. Reddy MM, Quinton PM. Selective activation of cystic fibrosis transmembrane conductance regulator CL- and HCO3- conductances. JOP 2001;2(4 Suppl):212-8.
24. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995;269:847-50.
25. Durno C, Corey M, Zielenski J, Tullis E, Tsui LC, Durie P. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology 2002;123:1857-64.
26. Ooi CY, Dorfman R, Cipolli M, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011;140:153-61.
27. Behrendorff N, Floetenmeyer M, Schwiening C, Thorn P. Protons released during pancreatic acinar cell secretion acidify the lumen and contribute to pancreatitis in mice. Gastroenterology 2010;139:1711-20, 1720.e1.
28. Pallagi P, Venglovecz V, Rakonczay Z Jr, et al. Trypsin reduces pancreatic ductal bicarbonate secretion by inhibiting CFTR Cl⁻ channels and luminal anion exchangers. Gastroenterology 2011;141:2228-2239.e6.
29. Hui DY, Howles PN. Carboxyl ester lipase: structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis. J Lipid Res 2002;43:2017-30.
30. Fjeld K, Weiss FU, Lasher D, et al. A recombined allele of the lipase gene
31. Fjeld K, Gravdal A, Brekke RS, et al. The genetic risk factor
32. El Jellas K, Dušátková P, Haldorsen IS, et al. Two new mutations in the
33. Witt H, Beer S, Rosendahl J, et al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet 2013;45:1216-20.
34. Moore PC, Cortez JT, Chamberlain CE, et al. Elastase 3B mutation links to familial pancreatitis with diabetes and pancreatic adenocarcinoma. J Clin Invest 2019;129:4676-81.
35. SARLES H, SARLES JC, MURATORE R, GUIEN C. Chronic inflammatory sclerosis of the pancreas-an autonomous pancreatic disease? Am J Dig Dis 1961;6:688-98.
36. Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995;40:1561-8.
37. Schneider A, Michaely H, Weiss C, et al. Prevalence and incidence of autoimmune pancreatitis in the population living in the southwest of Germany. Digestion 2017;96:187-98.
38. Kanno A, Masamune A, Okazaki K, et al. Research Committee of Intractable Diseases of the Pancreas. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011. Pancreas 2015;44:535-9.
39. Kamisawa T, Egawa N, Inokuma S, et al. Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy. Pancreas 2003;27:235-8.
40. Kamisawa T, Chari ST, Giday SA, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas 2011;40:809-14.
41. Sandrasegaran K, Menias CO. Imaging in autoimmune pancreatitis and immunoglobulin g4-related disease of the abdomen. Gastroenterol Clin North Am 2018;47:603-19.
42. Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013;62:1771-6.
43. John DS, Aschenbach J, Krüger B, et al. Deficiency of cathepsin C ameliorates severity of acute pancreatitis by reduction of neutrophil elastase activation and cleavage of E-cadherin. J Biol Chem 2019;294:697-707.
44. Ito T, Nakamura T, Fujimori N, et al. Characteristics of pancreatic diabetes in patients with autoimmune pancreatitis. J Dig Dis 2011;12:210-6.
45. Zamboni G, Lüttges J, Capelli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch 2004;445:552-63.
46. Shinagare S, Shinagare AB, Deshpande V. Autoimmune pancreatitis: a guide for the histopathologist. Semin Diagn Pathol 2012;29:197-204.
47. Ikeura T, Manfredi R, Zamboni G, et al. Application of international consensus diagnostic criteria to an Italian series of autoimmune pancreatitis. United European Gastroenterol J 2013;1:276-84.
48. Löhr JM, Faissner R, Koczan D, et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am J Gastroenterol 2010;105:2060-71.
49. Frulloni L, Lunardi C, Simone R, et al. Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med 2009;361:2135-42.
50. Mayerle J, Sendler M, Hegyi E, Beyer G, Lerch MM, Sahin-Tóth M. Genetics, cell biology, and pathophysiology of pancreatitis. Gastroenterology 2019;156:1951-1968.e1.
51. Halangk W, Lerch MM, Brandt-Nedelev B, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 2000;106:773-81.
52. Saluja A, Hashimoto S, Saluja M, Powers RE, Meldolesi J, Steer ML. Subcellular redistribution of lysosomal enzymes during caerulein-induced pancreatitis. Am J Physiol 1987;253:G508-16.
53. Ohmuraya M, Yamamura K. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases. Exp Anim 2011;60:433-44.
54. Wartmann T, Mayerle J, Kähne T, et al. Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice. Gastroenterology 2010;138:726-37.
55. Aghdassi AA, John DS, Sendler M, et al. Cathepsin D regulates cathepsin B activation and disease severity predominantly in inflammatory cells during experimental pancreatitis. J Biol Chem 2018;293:1018-29.
56. Gukovsky I, Gukovskaya AS, Blinman TA, Zaninovic V, Pandol SJ. Early NF-kappaB activation is associated with hormone-induced pancreatitis. Am J Physiol 1998;275:G1402-14.
57. Sendler M, Weiss FU, Golchert J, et al. Cathepsin B-mediated activation of trypsinogen in endocytosing macrophages increases severity of pancreatitis in mice. Gastroenterology 2018;154:704-718.e10.
58. Gukovskaya AS, Vaquero E, Zaninovic V, et al. Neutrophils and NADPH oxidase mediate intrapancreatic trypsin activation in murine experimental acute pancreatitis. Gastroenterology 2002;122:974-84.
59. Abdulla A, Awla D, Thorlacius H, Regnér S. Role of neutrophils in the activation of trypsinogen in severe acute pancreatitis. J Leukoc Biol 2011;90:975-82.
60. Awla D, Abdulla A, Syk I, Jeppsson B, Regnér S, Thorlacius H. Neutrophil-derived matrix metalloproteinase-9 is a potent activator of trypsinogen in acinar cells in acute pancreatitis. J Leukoc Biol 2012;91:711-9.
61. Mcguire M, Lipsky P, Thiele D. Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I. Journal of Biological Chemistry 1993;268:2458-67.
62. Turk D, Janjić V, Stern I, et al. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J 2001;20:6570-82.
63. Adkison AM, Raptis SZ, Kelley DG, Pham CT. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 2002;109:363-71.
64. Mayerle J, Schnekenburger J, Krüger B, et al. Extracellular cleavage of E-cadherin by leukocyte elastase during acute experimental pancreatitis in rats. Gastroenterology 2005;129:1251-67.
65. Aghdassi AA, John DS, Sendler M, et al. Absence of the neutrophil serine protease cathepsin G decreases neutrophil granulocyte infiltration but does not change the severity of acute pancreatitis. Sci Rep 2019;9:16774.
66. Leppkes M, Maueröder C, Hirth S, et al. Externalized decondensed neutrophil chromatin occludes pancreatic ducts and drives pancreatitis. Nat Commun 2016;7:10973.
67. Merza M, Hartman H, Rahman M, et al. Neutrophil extracellular traps induce trypsin activation, inflammation, and tissue damage in mice with severe acute pancreatitis. Gastroenterology 2015;149:1920-1931.e8.
68. Geisz A, Sahin-Tóth M. A preclinical model of chronic pancreatitis driven by trypsinogen autoactivation. Nat Commun 2018;9:5033.
69. Archer H, Jura N, Keller J, Jacobson M, Bar-Sagi D. A mouse model of hereditary pancreatitis generated by transgenic expression of R122H trypsinogen. Gastroenterology 2006;131:1844-55.
70. Mitsuyama T, Uchida K, Sumimoto K, et al. Comparison of neutrophil infiltration between type 1 and type 2 autoimmune pancreatitis. Pancreatology 2015;15:271-80.
71. Marinaccio L, Stefanucci A, Scioli G, et al. Peptide human neutrophil elastase inhibitors from natural sources: an overview. Int J Mol Sci 2022;23:2924.
72. Sjö P. Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors. Future Med Chem 2012;4:651-60.
73. Cao C, Yin C, Shou S, et al. Ulinastatin protects against LPS-induced acute lung injury by attenuating TLR4/NF-κB pathway activation and reducing inflammatory mediators. Shock 2018;50:595-605.
74. Testoni PA, Mariani A, Masci E, Curioni S. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis. Dig Liver Dis 2006;38:588-95.
75. Cao J, Liu Q. Protective effects of sivelestat in a caerulein-induced rat acute pancreatitis model. Inflammation 2013;36:1348-56.
76. Wang H, Wang S, Tang A, Gong H, Ma P, Chen L. Combined effects of sivelestat and resveratrol on severe acute pancreatitis-associated lung injury in rats. Exp Lung Res 2014;40:288-97.
